Drug Profile
NS 300
Alternative Names: NS300Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Neuracle Science
- Class Antibodies; Antiepileptic drugs; Neuropsychotherapeutics
- Mechanism of Action Neuropeptide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autistic disorder; Epilepsy; Neuropathic pain; Schizophrenia
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Neuropathic-pain in South Korea (Parenteral)
- 28 Feb 2022 No recent reports of development identified for research development in Autistic-disorder in South Korea (Parenteral)
- 28 Feb 2022 No recent reports of development identified for research development in Epilepsy in South Korea (Parenteral)